Evidence map›Paper›PMID 42893191›Full record

ArticlePhysics and imaging in radiation oncology2026

Feasibility of longitudinal prostate R

Chris Moore, Asher Ezekiel, Vodathi Bamunuarachchi, Ereny Saad, Anubhav Datta, Peter Hoskin, Ananya Choudhury, Marcel van Herk, David L Buckley, Michael J Dubec and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Physics and imaging in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chris MooreCMPE, The Christie NHS Foundation Trust, Manchester, UK.
Asher EzekielCMPE, The Christie NHS Foundation Trust, Manchester, UK.
Vodathi BamunuarachchiClinical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
Ereny SaadClinical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
Anubhav DattaDivision of Cancer Sciences, University of Manchester, Manchester, UK.
Peter HoskinDivision of Cancer Sciences, University of Manchester, Manchester, UK.
Ananya ChoudhuryDivision of Cancer Sciences, University of Manchester, Manchester, UK.
Marcel van HerkDivision of Cancer Sciences, University of Manchester, Manchester, UK.
David L BuckleyCMPE, The Christie NHS Foundation Trust, Manchester, UK.
Michael J DubecCMPE, The Christie NHS Foundation Trust, Manchester, UK.
Damien J McHughCMPE, The Christie NHS Foundation Trust, Manchester, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Purpose: Tissue R Materials and methods: Fifteen patients (seven with ADT) received five-fraction stereotactic-ablative-radiotherapy (SABR) on a 1.5 T Elekta Unity MRI-linac, with R Results: Whole-prostate R Conclusions: Treatment-induced whole-prostate and tumour R

Indexed as

HypoxiaImaging-BiomarkersMRI-linacProstate CancerR2*SABR

Identifiers

PMID42893191
PMCPMC13676080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.